These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15038945)

  • 1. Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis.
    Johnson P; Cihon C; Herrington J; Choudhri S
    Clin Ther; 2004 Feb; 26(2):224-31. PubMed ID: 15038945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB; Ferguson B; Twynholm M; Wynne B; Berkowitz E; Poole MD
    Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
    Lopez Sisniega J; Profant M; Kostrica R; Waskin H
    Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
    Dalhoff A; Krasemann C; Wegener S; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcus pneumoniae: susceptibility to penicillin and moxifloxacin.
    Rossi F; Franco MR; Rodrigues HM; Andreazzi D
    J Bras Pneumol; 2012; 38(1):66-71. PubMed ID: 22407042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM; Jacobs MR; Poole MD; Wynne B;
    Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.
    Siegert R; Gehanno P; Nikolaidis P; Bagger-Sjöbäck D; Ibanez JM; Hampel B; Sommerauer B
    Respir Med; 2000 Apr; 94(4):337-44. PubMed ID: 10845431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
    Norcross EW; Sanders ME; Moore Q; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):237-43. PubMed ID: 20565309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin.
    Johnson P; Adelglass J; Rankin B; Sterling R; Keating K; Benson A; Pertel P
    Int J Clin Pract; 2008 Sep; 62(9):1366-72. PubMed ID: 18671753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
    Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
    Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials.
    Karageorgopoulos DE; Giannopoulou KP; Grammatikos AP; Dimopoulos G; Falagas ME
    CMAJ; 2008 Mar; 178(7):845-54. PubMed ID: 18362380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and clinical course of invasive pneumococcal disease caused by penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae in Thai children.
    Siripongpreeda N; Hattasingh W; Amornvipas P; Eampokalap B; Sakoolgnam S; Pancharoen C; Thisyakorn U
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S1-5. PubMed ID: 21298829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis.
    Ferguson BJ; Guzzetta RV; Spector SL; Hadley JA
    Otolaryngol Head Neck Surg; 2004 Sep; 131(3):207-14. PubMed ID: 15365537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management.
    Block SL; Harrison CJ; Hedrick JA; Tyler RD; Smith RA; Keegan E; Chartrand SA
    Pediatr Infect Dis J; 1995 Sep; 14(9):751-9. PubMed ID: 8559623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.